By Connor Hart

Shares of Haemonetics jumped after the company reported higher profit in its fiscal second quarter and narrowed its full-year adjusted-earnings outlook toward the high end of its previous range.

The stock climbed 28% to $65 on Thursday. Shares have lost 17% of their value over the past year.

The medical-technology company before the bell posted a profit of $38.7 million, or 81 cents a share, for its three months ended Sept. 27, compared with $33.8 million, or 66 cents a share, in last year's comparable quarter.

Stripping out one-time items, earnings were $1.27 a share. Analysts surveyed by FactSet expected adjusted earnings of $1.11 a share.

Revenue fell 5.3% to $327.3 million but came in ahead of the $311.5 million that Wall Street had modeled.

Plasma and blood-center revenue fell 9.5% and 18%, respectively. That was partially offset by hospital revenue, which rose 5.1%.

"With the majority of our businesses outperforming and targeted actions underway to strengthen commercial execution in Interventional Technologies, we are firmly on track to deliver our updated fiscal year 2026 guidance and long-range plan objectives," Chief Executive Chris Simon said.

For its fiscal 2026, the company said it now expects total revenue to fall 1% to 4%, compared with a prior outlook of down 3% to 6%. It also raised the low end of its adjusted-earnings outlook to $4.80 a share from $4.70 a share, while maintaining the high end at $5 a share.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 06, 2025 13:34 ET (18:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.